Trading Update

Physiomics PLC

30 January 2025

 

30 January 2025

Physiomics plc

("Physiomics" or the "Company")

Trading Update

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that it is trading in line with market expectations for the full year ending 30 June 2025. 

The Board expects that total income for the current financial year, driven by contracts already signed, will be in line with market expectations. The Company is actively discussing a number of further contracts although there is no guarantee they will be signed within the current financial year. 

The Board also expects the Company's loss after tax for the same period will be slightly lower than current expectations. The Company has worked hard to maintain or increase its day rates with key customers and continues to improve operational efficiencies, both of which have contributed to the improved loss position.

The Company also notes that it expects to report its Interim Results for the six months ended 31 December 2024 in early March 2025.

Enquiries:

Physiomics plc

Dr Peter Sargent, CEO

[phone]

Hybridan LLP (Broker)

Claire Louise Noyce

[phone]

Strand Hanson Limited (NOMAD)

James Dance & James Bellman

[phone]

Notes to Editor

About Physiomics

Physiomics plc combines expertise across Modelling & Simulation, Biostatistics, Data Science and Bioinformatics, together with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to help derive insight from all relevant and often disparate data in order to de-risk decision making and optimise research design across discovery, pre-clinical and clinical studies. Through use of cutting-edge computational tools, bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 commercial projects, with over 125 targets and drugs modelled. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.   

This announcement contains inside information for the purposes of article 7 of the Market Abuse Regulation (EU) 596/2014 as amended by regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310. With the publication of this announcement, this information is now considered to be in the public domain.

 

END